Regular articleA cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil
Section snippets
Materials and methods
The study was a prospective observational study in patients enrolled in nine centers in Brazil between March 2000 and July 2002. The study was approved by the institutional review board and ethics committees at each study center. The cost analysis was conducted from the perspective of the Brazilian health care system.
Patient characteristics
A total of 157 patients were enrolled in the study, of which 67 were excluded from the analysis because they were lost to follow-up after the first visit to the clinic (Fig. 1). In the overall population, 32 (20.4%) had mild-to-moderate PTS, defined according to the criteria in Table 1, and 125 (79.6%) had severe PTS.
Of the 90 patients included in the analysis, 17 (18.8%) had mild-to-moderate PTS and 73 (81.1%) had severe PTS. There were no significant differences in the demographic
Discussion
The results of this observational study show that the treatment of PTS imposes significant economic costs in Brazil, largely due to the need for hospitalization in patients with the most severe symptoms and greater use of wound dressings in these patients. These findings are consistent with those of other studies, which have shown that the management of PTS is associated with substantial medical costs [4], [7].
The use of thromboprophylaxis to prevent DVT in high-risk patients is likely to
Acknowledgments
This study was funded by an unrestricted educational grant from sanofi-aventis.
References (22)
- et al.
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis
Lancet
(1997) - et al.
Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States
Value Health
(2003) - et al.
Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy
Chest
(2004) - et al.
Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy
Chest
(2004) - et al.
Use of elastic compression stockings after deep venous thrombosis: a comparison of practices and perceptions of thrombosis physicians and patients
J Thromb Haemost
(2003) - et al.
The long-term clinical course of acute deep venous thrombosis
Ann Intern Med
(1996) - et al.
Prevention and treatment of postphlebitic syndrome: results of a 3-part study
Arch Intern Med
(2001) - et al.
Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden
Ann Intern Med
(1997) - et al.
Long-term outcomes of deep-vein thrombosis
Arch Intern Med
(1995) - et al.
Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis
Arch Intern Med
(2002)
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
N Engl J Med
Cited by (22)
Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: A systematic review and meta-analysis
2020, Thrombosis ResearchCitation Excerpt :Although DOACs have been proved to bring more benefits for DVT patients in many aspects, some DOAC-suitable patients may end up being treated with VKAs due to economic reasons, particularly in the developing countries [33,34]. However, as the annual cost of treating PTS can be huge [35–38], rivaroxaban may have the potential to present an even better economic profile than VKAs because of its association with substantially lower risk of PTS observed in this meta-analysis. Thus, our findings warrant further studies that directly investigate the long-term costs for the treatment of VTE and its post-thrombotic sequelae in rivaroxaban versus VKAs treated patients.
Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban
2020, Vascular PharmacologyCitation Excerpt :Exclusion criteria included indeterminate time of the anticoagulation therapy, other treatment than enoxaparin/warfarin or rivaroxaban, current use of anticoagulants or corticosteroids, infectious or inflammatory disease, pregnancy or puerperium, active or diagnosis of cancer in the previous 6 months and unwillingness or inability to provide informed consent. This is a cross-sectional study in which patients with DVT anticoagulated with either rivaroxaban or enoxaparin/warfarin were evaluated after 15 months [10–24] and after 61 months (34–86.5) following finalization of treatment for DVT, respectively. Patients selected for the study were contacted by telephone and were invited for the first study visit at the Outpatient Clinic of Hemocentro de Campinas after they complied with all inclusion and exclusion criteria.
Postthrombotic Syndrome: Long-Term Sequela of Deep Venous Thrombosis
2018, American Journal of the Medical SciencesCitation Excerpt :Moreover, another report revealed a proportionate correlation between the severity of PTS and the annual treatment cost. The effect of PTS on annual U.S. healthcare costs was conservatively estimated at $200 million annually (in 1990 U.S. dollars).42-45 Anticoagulation therapy plays an essential role in PTS prevention by preventing recurrence or propagation of DVT.
Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis
2013, Journal of Thrombosis and HaemostasisPost-thrombotic syndrome and chronic thromboembolic pulmonary hypertension: diagnosis and management
2023, British Journal of Hospital Medicine